目的 :评价地洛他定治疗过敏性鼻炎的临床疗效和安全性。方法 :采用多中心、随机、双盲、阳性药物平行对照研究。入选过敏性鼻炎病人 2 4 0例 ,完成 2 2 4例 ,其中地洛他定组 114例 ,男性 5 5例 ,女性 5 9例 ,年龄 (4 0±s 7)a ,病程 (6 6± 9)mo ,服用地洛他定 ,5mg,po ,qd ;氯雷他定组 110例 ,男性 4 5例 ,女性 6 5例 ,年龄 (39± 7)a ,病程 (6 3± 8)mo ,予氯雷他定 ,10mg,po ,qd。 2组疗程均为2wk ,观察 2组疗效和不良反应。结果 :地洛他定用于治疗过敏性鼻炎 2wk后的显效例数和有效率分别为 4 6例和 92 .1% ,氯雷他定组的显效例数和有效率分别为 32例和 88.2 %。 2组疗效差异无显著意义 (P >0 .0 5 )。 2组均未出现严重及预料之外的不良反应 ,地洛他定组和氯雷他定组的不良反应发生率分别为 8.3%和 15 .0 % ,P >0 .0 5。结论 :地洛他定治疗过敏性鼻炎具有明显疗效 ,不良反应轻微 Objective: To evaluate the clinical efficacy and safety of dextaxidine in the treatment of allergic rhinitis. Methods: A multicenter, randomized, double-blind, positive-drug parallel control study was performed. A total of 240 cases of allergic rhinitis were enrolled, of whom 224 cases were completed, including 114 cases of desloratadine group, 55 cases of male and 59 cases of female, age (40 ± s 7) a, duration 9) mo, taking loratadine, 5mg, po, qd; loratadine group 110 patients, 45 males and 65 females, age (39 ± 7) a, duration , To loratadine, 10mg, po, qd. 2 groups were 2wk treatment, observation of two groups of side effects and adverse reactions. Results: The effective and effective rates of dexratadine in treating allergic rhinitis after 2 weeks were 46 cases and 92.1% respectively. The effective cases and the effective rates in loratadine group were 32 cases and 88.2 cases %. There was no significant difference between the two groups (P> 0.05). There were no serious and unexpected adverse reactions in both groups. The incidence of adverse reactions in the dextro-tautidine and loratadine groups was 8.3% and 15.0%, respectively, P> 0.05. Conclusion: Deoxytaxidine treatment of allergic rhinitis has a significant effect, minor adverse reactions